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Background: There is little evidence of the efﬁcacy and safety of dabigatran in Japanese patients with
non-valvular atrial ﬁbrillation (NVAF).
Methods and Results: We evaluated 300 consecutive patients with NVAF (68711 years old, 209 men, 180
paroxysmal) who received 220 mg/day (203 patients) or 300 mg/day dabigatran (97 patients) at our
hospital. Most patients (84%) had lower CHADS2 (congestive heart failure, hypertension, age475 years,
diabetes, stroke/transient ischemic attack) scores of 0 (n¼60), 1 (n¼114), or 2 (n¼78) and lower HAS-
BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition) scores of 0
(n¼39), 1 (n¼114), or 2 (n¼103). The estimated creatinine clearance was 77724 mL/min, which was
inversely correlated to age (r2¼0.48, po0.0001). Activated partial thromboplastin time was 4279 s but
was not dependent on sampling time. During follow-up of 2637160 days, an ischemic stroke occurred in
1 patient (0.3%), but no systemic embolism was observed. Some adverse events were reported for 70
(23%) patients, such as dyspepsia (n¼42, 14%) or minor bleeding complications (n¼11, 4%) resulting in
discontinuation of dabigatran for 39 patients. However, no major complications were observed, and no
patient died from adverse events or because of cardiovascular or stroke events.
Conclusions: Dabigatran is safe and useful for the prevention of ischemic strokes in Japanese NVAF
patients, but additional care should be taken for elderly patients.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
The prevalence of atrial ﬁbrillation (AF) increases with age, and
Japan has one of the fastest aging populations in the world.
Warfarin is highly effective in reducing the risk of stroke in patients
with AF. However, warfarin is subject to several shortcomings, such
as its narrow therapeutic window, need for frequent coagulation
monitoring, slow onset and offset of action, and numerous drug and
food interactions [1,2]. Moreover, there are no net clinical beneﬁts
of warfarin for patients with non-valvular AF (NVAF) and lower
CHADS2 (congestive heart failure, hypertension, age475 years,
diabetes, stroke/transient ischemic attack) scores of 0–1 [3]. There-
fore, physicians have often been hesitant to prescribe anticoagulation
therapy for NVAF patients with lower CHADS2 scores.t Rhythm Society. Published by Els
r Medicine, National Cerebral
ita, Osaka 565-8565 Japan.Dabigatran is a novel oral anticoagulant that is a potent, direct,
competitive, and reversible inhibitor of thrombin. The RE-LY,
a randomized evaluation trial of long-term anticoagulation therapy
and its sub-analysis, demonstrated that dabigatran (220 or 300 mg/
day) has many clinical advantages for anticoagulation in patients
with NVAF as compared with warfarin [4–7]. Therefore, dabigatran
has been approved in many countries for the prevention of strokes
in patients with NVAF [8,9]. However, there is little clinical evidence
for its use in Japanese AF patients [10–12]. Furthermore, severe
bleeding complications after dabigatran administration have been
reported in some Japanese patients [13]. Thus, the aim of this study
was to clarify the efﬁcacy and safety of anticoagulation with
dabigatran in Japanese patients with NVAF.2. Methods
2.1. Patients
This study involved 300 consecutive NVAF patients who received
dabigatran from April 2011 to August 2012 at the Department ofevier B.V. All rights reserved.
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Center. Dabigatran was prescribed at 220 mg/day (203 patients: 68%)
or 300 mg/day (97 patients: 32%). The primary physician of the patient
determined the dosage. We retrospectively analyzed the clinical
characteristics and short-term efﬁcacy and safety after dabigatran
therapy in these patients.
2.2. Deﬁnition of stroke, hemorrhage, and renal function
Stroke was deﬁned as the sudden onset of a focal neurological
deﬁcit in a location consistent with the territory of a major
cerebral artery, and categorized as ischemic, hemorrhagic, or
unspeciﬁed. Systemic embolism was deﬁned as an acute vascular
occlusion of an extremity or organ documented by imaging,
surgery, or autopsy. Intracranial hemorrhage included hemorrha-
gic stroke and subdural or subarachnoid hemorrhage [4].
Major bleeding was deﬁned as a decrease in hemoglobin≥2
g/dL, a transfusion of ≥2 units of whole blood or packed red blood
cells, or symptomatic bleeding in a critical area or organ. Minor
bleeding was deﬁned as clinically overt bleeding that did not meet
the criteria for major bleeding. Estimated creatinine clearance
(eCCr) was calculated using Cockcroft–Gault equations [14].
eCCr¼ ð140−ageÞ  body weightðkgÞ  ½0:85 if female
72 serum creatinineðmg=dLÞ
Deteriorating renal function was deﬁned as an eCCr decrease to
o30 mL/min or at the discretion of the primary physician to
discontinue dabigatran due to the eCCr decrease.
2.3. CHADS2, CHA2DS2-VASc, and HAS-BLED Scores
We assessed stroke risk using the CHADS2 and CHA2DS2-VASc
scores [15,16]. The CHADS2 score assigns 1 point each for con-
gestive heart failure (CHF), hypertension (HT), age≥75 years, and
diabetes mellitus (DM) and 2 points for a history of stroke or
transient ischemic attack (TIA) [15]. The CHA2DS2-VASc score
assigns 1 point each for CHF, HT, age 65–74 years, DM, vascular
disease, female sex; and 2 points for age≥75 years, and a history of
stroke or TIA [16]. The HAS-BLED (hypertension, abnormal renal/
liver function, stroke, bleeding history or predisposition, labile
international normalized ratio, elderly (≥75 years), drugs/alcohol)
score is used to assess the risk for cerebral and systemic bleeding,
scoring HT, abnormal renal/liver function (1 point each), stroke,Table 1
Patient characteristics.
Dabigatran Total (n¼300) Dab
Age, years 68711 727
≥75, n (%) 88 (29) 86 (
Sex, n (M/F) 209/91 128
Weight (kg) 64711 617
Serum Cr (mg/dL) 0.8370.16 0.83
eCCr (mL/min) 77724 687
AF, n: (paroxysmal/persistent) 180/120 123
Previous stroke or TIA, n (%) 41 (14) 33 (
LA diameter (mm) 4177 417
Structural heart disease, n (%) 81 (27) 64 (
Congestive heart failure, n (%) 53 (18) 41 (
Hypertension, n (%) 179 (60) 133
Diabetes mellitus, n (%) 45 (15) 33 (
Drugs for peptic ulcer, n (%) 155 (52) 102
Concomitant use of anti-platelet agent, n (%) 27 (9) 26 (
Previous medication use
Warfarin, n (%) 121 (40) 89 (
Anti-platelet agent, n (%) 16 (5) 10 (
Follow-up period (days) 2637160 264
Cr¼Creatinine, AF¼atrial ﬁbrillation, LA¼ left atrium, TIA¼transient ischemic attack, eCbleeding history or predisposition, labile international normalized
ratio, elderly (≥75 years), and drugs/alcohol (1 point each) [15].
If a HAS-BLED score is ≥3, a patient is considered to have a
measurable risk of bleeding [9,17].
2.4. Radiofrequency catheter ablation procedure
The patients for whom radiofrequency (RF) catheter ablation
was indicated for AF received dabigatran at least 30 days before RF
catheter ablation. The Supplemental Methods describe the RF
ablation procedure in detail. Periprocedural anticoagulation was
based on a predetermined algorithm. Dabigatran was discontinued
the evening prior to the day of RF ablation, and continuous heparin
infusion of 10,000–15,000 U/day was administered until 3 h before
the RF ablation procedure, and resumed after hemostasis until
24 h after the procedure. Dabigatran was resumed about 24 h after
RF ablation at the same dose as that administered before the
procedure.
2.5. Activated partial thromboplastin time measurement
Activated partial thromboplastin time (APTT) was measured
several times after dabigatran administration. Primary physician
decided when to collect blood sample. We investigated the
relationship between APTT and its sampling time in each dabiga-
tran dose. The APTT measurement was repeated at almost the
same time during follow-up, and these APTT values were com-
pared for reproducibility.
2.6. Follow-up
Patients visited our institute, another hospital, or their primary
physician within 2–4 weeks of dabigatran being ﬁrst prescribed;
if no bleeding or other adverse events were observed, patients
were followed up at least every 3 months.
2.7. Statistical analysis
Data are expressed as mean7SD. Data were analyzed by
unpaired t-test if they were normally distributed. The χ2 test was
used to analyze the independence of the 2 classiﬁcation criteria in
the qualitative data. The comparison of the APTT values of each
patient was analyzed using the paired t-test, followed by theigatran 220 mg/day (n¼203) Dabigatran 300 mg/day (n¼97) p-value
8 5979 o0.0001
42) 2 (2) o0.0001
/75 81/16 0.0003
10 70712 o0.0001
70.17 0.8370.14 ns
19 95724 o0.0001
/80 57/40 ns
16) 8 (8) 0.06
7 4178 ns
32) 17 (18) 0.01
20) 12 (12) ns
(66) 46 (47) 0.0028
16) 12 (12) ns
(50) 53 (55) ns
13) 1 (1) 0.0009
44) 32 (33) 0.07
5) 6 (6) ns
7161 2597159 ns
Cr¼estimated creatinine clearance, ns¼not signiﬁcant.
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statistically signiﬁcant.3. Results
3.1. Patient Characteristics
Table 1 lists the baseline characteristics of the patients in this
study. The mean age was 68711 years; patients aged 70–75 years
were the most numerous in the sample (Fig. 1a). There were 209male
patients. On average, the patients receiving 300mg/day dabigatran
were younger and heavier than those on 220mg/day dabigatranwere
(5979 vs. 7278 years old; po0.0001, and 70712 vs. 61710 kg;
po0.0001, respectively). Nearly all patients aged 475 years (98%)
received 220 mg/day dabigatran. Sixty percent (n¼180) of AF was
paroxysmal and the remaining 40% (n¼120) was persistent. Forty-one
patients (14%) had suffered a prior stroke or TIA.
The averaged left atrium diameter was 4177 mm. Eighty-one
patients (27%) had structural heart disease such as cardiomyo-
pathy (n¼14) and ischemic heart disease (n¼21), and 53 patients
(18%) had CHF. One hundred seventy-nine patients (60%) had HT,
and 45 (15%) had DM. The frequency of age≥75 years; female sex;
and number of patients with structural heart disease, HT, and
concomitant use of an anti-platelet agent were signiﬁcantly
greater in the patients on 220 mg/day dabigatran than those on
300 mg/day dabigatran were (Table 1).0
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Fig. 1. (a) Relationship between age and number of patients who received dabigatran
(red¼300 mg/day, blue¼220 mg/day). Fig. 1 and (b) Relationship between eCCr and
number of patients who received dabigatran (red¼300 mg/day, blue¼220mg/day).
eCCr¼estimated creatinine clearance.One hundred twenty-one patients (40%) switched from
warfarin to dabigatran and 16 patients (5%) switched from their
anti-platelet agent to dabigatran for anticoagulant therapy. An
anti-platelet agent was prescribed concomitantly with dabigatran
in 27 patients (9%) mainly due to ischemic heart disease. The
frequency of concomitant use of an anti-platelet agent was higher
in elderly patients (≥75 years old) as compared with younger
patients (13 of 88; 15% vs. 14 of 212; 7%, respectively; p¼0.02).
RF catheter ablation was performed in 73 patients (24%).
Table 2 displays the distribution of the CHADS2, CHA2DS2-VASc,
and HAS-BLED scores. The CHADS2 score was 0 in 60 patients
(20%), 1 in 114 (38%), 2 in 78 (26%), and ≥3 in 48 (16%); thus, the
mean score was 1.571.2. The CHA2DS2-VASc score was 0 in 26
patients (9%), 1 in 61 (20%), 2 in 65 (22%), and ≥3 in 148 (49%). The
mean CHA2DS2-VASc score was 2.671.7. The HAS-BLED score was
0 in 39 patients (13%), 1 in 114 (38%), 2 in 103 (34%), and ≥3 in 44
(15%). The mean HAS-BLED score was 1.571.0.
The CHADS2, CHA2DS2-VASc, and HAD-BLED scores were
higher for patients receiving 220 mg/day dabigatran than those
receiving 300 mg/day dabigatran.
3.2. Thromboembolic events
Ischemic stroke occurred in one 60-year-old male patient (Table 3)
with persistent AF after RF ablation. The patient had received 220 mg/
day dabigatran for 1 month before the RF procedure. His eCCr was
91 mL/min and his CHADS2 score was 1 (DM). Vision disturbance due
to left occipital lobe infarction occurred 1 day after the RF procedure.
Dabigatran was increased from 220mg/day to 300mg/day after the
event. His neurological symptoms improved during the follow-up
period. No stroke events occurred in the remaining patients during
follow-up of 2637160 days; no patient experienced systemic
embolism during the follow-up period.
3.3. Adverse events and discontinuation
Adverse events by dabigatran were observed in 70 (23%)
patients (Table 3). No major complications, including intracranial
hemorrhage, occurred during the follow-up period. Minor bleed-
ing complications occurred in 11 patients (4%), including 1 patient
with gastrointestinal bleeding. Forty-two (14%) patients hadTable 2
CHADS2, CHA2DS2-VASc, and HAS-BLED scores.
Dabigatran
Total
(n¼300)
Dabigatran
220 mg/day
(n¼203)
Dabigatran
300 mg/day
(n¼97)
p-value
CHADS2
score, mean
1.571.2 1.871.3 0.970.8 o0.0001
0; n (%) 60 (20) 25 (12) 35 (36) o0.0001
1; n (%) 114 (38) 74 (36) 40 (41) ns
2; n (%) 78 (26) 60 (30) 18 (19) 0.04
≥3; n (%) 48 (16) 44 (22) 4 (4) 0.0001
CHA2DS2-
VASc score,
mean
2.671.7 3.171.6 1.471.2 o0.0001
0; n (%) 26 (9) 1 (0.5) 25 (26) o0.0001
1, n (%) 61 (20) 27 (13) 34 (35) o0.0001
2; n (%) 65 (22) 47 (23) 18 (19) ns
3; n (%) 74 (25) 59 (29) 15 (15) 0.01
4; n (%) 40 (13) 35 (17) 5 (5) 0.004
≥5; n (%) 34 (11) 34 (17) 0 (0) o0.0001
HAS-BLED
score, mean
1.571.0 1.970.9 0.970.8 o0.0001
0, n (%) 39 (13) 5 (2) 34 (35) o0.0001
1; n (%) 114 (38) 70 (34) 44 (45) 0.07
2; n (%) 103 (34) 86 (42) 17 (18) o0.0001
≥3, n (%) 44 (15) 42 (21) 2 (2) o0.0001
Table 3
Thromboembolic event, adverse events, and discontinuation of dabigatran.
Dabigatran Total (n¼300) Dabigatran 220 mg/day (n¼203) Dabigatran 300 mg/day (n¼97) p-value
Thromboembolic event, n 1 (0.3) 1 (0.5) 0 (0) 0.49
Adverse events, n (%) 70 (23) 52 (26) 18 (19) 0.18
Major bleeding, n (%) 0 (0) 0 (0) 0 (0) –
Minor bleeding, n (%) 11 (4) 9 (4) 2 (2) 0.31
Dyspepsia, n (%) 42 (14) 32 (16) 10 (10) 0.20
Swallowing difﬁculty, n (%) 5 (2) 3 (1) 2 (2) 0.71
Deteriorating renal function, n (%) 4 (1) 4 (2) 0 (0) 0.16
Diarrhea, n (%) 3 (1) 2 (1) 1 (1) 0.97
Rash, n (%) 3 (1) 2 (1) 1 (1) 0.97
Itching, n (%) 2 (1) 1 (0.5) 1 (1) 0.59
Discontinuation, n (%) 65 (22) 40 (20) 25 (26) 0.23
Temporal use for RF ablation, n (%) 23 (8) 7 (3) 16 (16) o0.0001
Side effects, n (%) 39 (13) 30 (15) 9 (9) 0.19
RF¼radiofrequency.
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Fig. 2. Relationship between age and eCCr. The eCCr was inversely correlated to age
(po0.0001). eCCr¼Estimated creatinine clearance.
Table 4
Patients for whom dabigatran was discontinued due to decrease in eCCr.
# Age
(years)
Sex Dabigatran
(mg/day)
Follow-up
(days)
CHADS2 eCCr
(mL/min)
(baseline)
eCCr
(mL/min)
(on dabigatran)
1 60 F 220 369 3 62.2 28.5
2 76 F 220 376 3 38.6 28.3
3 88 M 220 404 6 48.8 29.5
4 72 M 220 42 2 51.4 36.7
K. Miyamoto et al. / Journal of Arrhythmia 30 (2014) 58–64 61dyspepsia such as upper abdominal pain, abdominal pain, and
abdominal discomfort. None died from adverse events or cardio-
vascular and stroke events. There was no signiﬁcant difference in
the frequency of adverse events between patients receiving
220 mg/day and 300 mg/day dabigatran.
Sixty-ﬁve patients discontinued dabigatran, with 39 patients (60%)
discontinuing it due to adverse events such as dyspepsia (n¼21),
deteriorating renal function (n¼4), minor bleeding (n¼3), swallow-
ing difﬁculty (n¼2), or rash (n¼2). Due to the prolongation of APTT
(65 s and 59 s each), dabigatran was discontinued for another
2 patients at the discretion of their primary physicians. Of these 41
patients, 26 (63%) subsequently switched to warfarin, 8 patients to
rivaroxaban, and 4 patients to aspirin. One patient died from
malignant mesothelioma during the follow-up period. The remaining
23 patients discontinued dabigatran because they used it temporarily
for RF ablation. The follow-up period (dabigatran prescription period)
of these 23 patients was 190792 days. There was no signiﬁcant
difference in the frequency of discontinuation between patients
receiving 220 mg/day and 300mg/day dabigatran.
Drugs for peptic ulcer were prescribed for 155 of the 300
patients (52%): 128 patients (43%) received a proton pump
inhibitor and 17 patients (6%) received an H2-blocker. In 42
patients with dyspepsia, drugs for peptic ulcer were prescribed
in 28 patients (67%), of whom 24 received a proton pump inhibitor
and 2 received an H2-blocker. The drugs for peptic ulcer were
effective in curing the dyspepsia in 9 patients (proton pump
inhibitor in 8 patients, H2-blocker in 1 patient).
3.4. Dabigatran and renal function
The averaged serum creatinine was 0.83 mg/dL, and there was
no difference between patients who received 220 mg/day and
300 mg/day dabigatran. However, as the patients on 300 mg/day
dabigatran were heavier and younger, their mean eCCr was higher
than that in those who received 220 mg/day dabigatran (95724
vs. 68719 mL/min; po0.0001). An eCCro50 mL/min was
observed in 26 of 203 patients (13%) who received 220 mg/day
dabigatran, whereas the eCCr of all 97 patients who received 300
mg/day dabigatran was 450 mL/min (p¼0.0002) (Fig. 1b).
Fig. 2 illustrates the relationship between eCCr and age, where
the eCCr was inversely correlated to the age of patients (r2¼0.484,
po0.0001). The eCCr at 1417125 days after dabigatran adminis-
tration could be calculated again in 235 of the 300 patients.
We decided to discontinue dabigatran in 3 patients because their
eCCr fell to o30 mL/min after dabigatran administration (Table 4).
The baseline eCCr of these 3 patients was 62.2, 38.6, and 48.8 mL/
min, respectively, decreasing to 28.5, 28.3, and 29.5 mL/min,
respectively, during follow-up. Another 72-year-old mandiscontinued dabigatran at the discretion of his primary physician
because his eCCr decreased to 36.7 mL/min from 51.4 mL/min.
These 4 patients had all received 220 mg/day dabigatran.
3.5. Dabigatran and APTT
The APTT could be evaluated in 233 patients and the mean
APTT was 4279 s. There was no signiﬁcant difference in mean
APTT values between patients on 220 mg/day and 300 mg/day
dabigatran (4279 s vs. 4179 s). Fig. 3 illustrates the relationship
between the APTT and eCCr values. APTT was inversely correlated
to eCCr (r2¼0.04, p¼0.0087).
eCCr (ml/min) 
A
P
TT
 (s
) 
APTT = 66.6 – 5.81*Log (CCr) 
R2 = 0.04 
Fig. 3. Relationship between APTT values and eCCr. The APTT was inversely
correlated to the eCCr. APTT¼Activated partial thromboplastin time, eCCr¼esti-
mated creatinine clearance.
A
P
TT
 (s
) 
Time of day 
300mg/day
220mg/day
Fig. 4. Relationship between APTT values and sampling time (time of day). The APTT
was not dependent on the time of day for each dabigatran dose (blue¼220 mg/day,
red¼300 mg/day). APTT¼Activated partial thromboplastin time.
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time at each dabigatran dose. There was a wide distribution in the
APTT values among patients at each dabigatran dose, and the APTT
was not dependent on the sampling time because patients were
not permitted to change the time they took the dabigatran. The
mean APTT measured on another day (4179 s) was almost the
same as that recorded at the ﬁrst use of dabigatran: 4179 s. There
was no statistical difference (p¼0.41) between the ﬁrst and
second APTT measurements. The day-to-day difference of the
APTT values of each patient was not substantial (Supplemental
Figure), indicating that the APTT values were highly reproducible.
Patients with minor bleeding events had greater APTT values as
compared to those without minor bleeding events, but this was
not statistically signiﬁcant (mean, 48712 s vs. 4179 s; p¼0.052).4. Discussion
4.1. Main ﬁndings
We obtained several ﬁndings from this study. First, dabigatran
is safe for the prevention of stroke in clinical practice for Japanese
NVAF patients. Second, careful monitoring of laboratory data,
including the eCCr, is necessary, especially in elderly patients
and/or those with renal dysfunction because deteriorating renal
function may occur during anticoagulation treatment using dabi-
gatran. Third, the APTT values varied greatly but had high
reproducibility; therefore, the APTT may be a suitable parameter
for screening bleeding risk.
4.2. Advantages of dabigatran
Although patients with CHADS2 scores of 0 or 1 face a certain
degree of stroke risk, the bleeding risk with warfarin may out-
weigh the beneﬁt [3]. On one hand, sub-analysis of the RE-LY
indicated that dabigatran is more effective and safer for AF
patients with lower CHADS2 scores (0 or 1) as compared to
warfarin [5]. The European AF guidelines propose that when
anticoagulation for AF is recommended, a direct thrombin inhi-
bitor (dabigatran) or a factor Xa inhibitor should be considered
based on their net clinical beneﬁt rather than adjusted-dose
warfarin for most patients with NVAF [9]. The sub-analysis of
the RE-LY demonstrated that the efﬁcacy and safety proﬁles of
dabigatran for Japanese AF patients were almost the same as that
for the entire study population in the RE-LY [10]. Based on the RE-
LY, the Japanese Circulation Society recently released a statement
recommending the use of dabigatran for patients with a CHADS2
score of 1, whereas the use of warfarin remained within con-
sideration for a CHADS2 score of 1 [18]. No major bleeding event
occurred in this study. Therefore, dabigatran is safe for the
prevention of ischemic stroke for Japanese NVAF patients in
clinical practice as well.
4.3. Utility of APTT
Although it has been reported that the APTT is correlated with
the anticoagulant effect of dabigatran at lower plasma concentra-
tions, it does not denote an accurate quantitative value of the
anticoagulant effect at higher concentrations [19,20]. In addition,
the time to peak concentration of dabigatran is affected by factors
such as age, sex, and renal function [21,22], and there is a wide
distribution in the APTT values among patients receiving dabiga-
tran, as shown in this study (Fig. 4). This study, however, demon-
strated the reproducibility of the APTT values of each patient.
In addition, we demonstrated that the APTT value is not greatly
affected by sampling time. Although it may be difﬁcult to use APTT
as a marker of anticoagulant efﬁcacy for dabigatran, it might be
useful for screening bleeding risk among patients receiving dabi-
gatran [11]. In this study, the APTT value was higher in patients
with minor bleeding as compared with those with no bleeding.
Therefore, APTT, which can be measured comparatively easily
in outpatient settings, might be a useful marker for bleeding
complication.
4.4. Shortcomings of dabigatran
There is no speciﬁc antidote to reverse the effects of dabigatran.
Major gastrointestinal bleeding and dyspepsia were more common
with dabigatran than with warfarin in the RE-LY [4]. Drugs for
peptic ulcer, including proton pump inhibitors, were more fre-
quently prescribed in this study than in the RE-LY (52% vs. 15%,
respectively), and only 1 patient suffered minor gastrointestinal
K. Miyamoto et al. / Journal of Arrhythmia 30 (2014) 58–64 63bleeding in this study. Therefore, drugs for peptic ulcer may be
useful for the prevention of gastrointestinal bleeding. Drugs for
peptic ulcer were effective for our patients with dyspepsia to some
extent, so they may also be useful for curing dyspepsia during
dabigatran treatment.
4.5. The relationship between dabigatran and renal function
Dabigatran is often described as an anticoagulant that does not
require routine coagulation monitoring because its pharmacoki-
netics are predictable [23]. However, many patients with AF are
aged, and the elderly often have comorbidities such as DM, which
are important risk factors for the deterioration of renal function
[24]. In addition, advanced age itself is a risk factor for renal
dysfunction [25]. In this study, the eCCr was inversely correlated
with age (Fig. 2). Moreover, the elderly often have vascular
diseases, e.g., ischemic heart disease, as comorbidities and require
treatment with anti-platelet agents. Eikelboom et al. reported that
the risk of bleeding increased with age, decreased CCr, and with
concomitant use of anti-platelet agents [26]. In addition, gastro-
intestinal bleeding, which is one complication of dabigatran
treatment, is not always accompanied by epigastric symptoms
[27]. Therefore, ﬁxed-dose dabigatran without monitoring may
lead to a higher risk of bleeding. We recommend that laboratory
data, including renal function, hematological value, and APTT, be
monitored in particular in elderly patients who possess the risk
factors for deterioration of renal function, such as DM and/or
concomitant use of an anti-platelet agent, and/or higher HAS-BLED
scores.
4.6. The relationship between dabigatran and RF ablation
There is some evidence for the efﬁcacy and safety of dabigatran
in patients undergoing RF ablation for AF. Lakkireddy et al.
compared the efﬁcacy and safety of dabigatran and warfarin in
periprocedural anticoagulation in patients undergoing RF ablation
for AF [28]. They reported that periprocedural use of dabigatran
signiﬁcantly increased the risk of thromboembolic and bleeding
complications as compared with uninterrupted warfarin therapy.
In contrast, Kaseno et al. reported that the periprocedural use of
dabigatran was useful and safe in Japanese patients [12]. In this
study, ischemic stroke occurred in 1 patient as a periprocedural
complication of RF ablation. Therefore, it is necessary to investi-
gate the efﬁcacy and safety of dabigatran in RF ablation with a
large patient sample and identify appropriate strategies for peri-
procedural anticoagulation.
4.7. Study limitations
We performed this study to evaluate the efﬁcacy and safety of
dabigatran in Japanese patients with NVAF; therefore, we did not
compare it with warfarin. This study was retrospective and
nonrandomized, and involved a small sample at a single cardio-
vascular center. In addition, the follow-up period was short.
Further investigations are necessary to demonstrate the efﬁcacy
and safety of dabigatran. As the mean CHADS2 score in this study
was relatively low (1.571.2 points), the efﬁcacy and safety of
dabigatran in clinical use are uncertain in patients with high
CHADS2 scores.5. Conclusions
In clinical practice, dabigatran is useful and safe for the
prevention of ischemic stroke in Japanese NVAF patients. Monitor-
ing of laboratory data is necessary in patients receiving dabigatran,especially for elderly patients who have renal dysfunction and/or
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